Press Resease

Pharmacovigilance Market - Global Industry Analysis

Pharmacovigilance Market by Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4), by Service Provider (In-House and Contract Outsourcing), by Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining), and by End-User (Hospitals, Research Organizations, and Industries): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 20-May-2019 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-1418 Status : Published

Global pharmacovigilance market expected to generate around USD 8.33 billion by 2025, at a CAGR of around 11.6% between 2019 and 2025. The global pharmacovigilance market is driven by the rising awareness about the safety and efficacy of drugs among the worldwide population and the growing demand for substantially adopting safe medical practices.

Description

The report covers a forecast and an analysis of the pharmacovigilance market on a global and regional level. The study provides historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Billion). The study includes the drivers and restraints of the pharmacovigilance market along with their impact on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the pharmacovigilance market on a global level.

In order to give the users of this report a comprehensive view of the pharmacovigilance market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Pharmacovigilance Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product, and regional expansion of major participants involved in the market.

The study provides a decisive view on the pharmacovigilance market by segmenting it on the basis of clinical trial phase, service provider, method, end-user, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., UK, Germany, France, China, Japan, India, Brazil, etc.

Some key players in the global pharmacovigilance market include as F. Hoffmann-La Roche, Cognizant, Pharmaceutical Clinical Trial Phase Development, Bristol-Myers Squibb, Covance, ICON, Accenture, Pfizer, Clinquest Group, Novartis International, GlaxoSmithKline, PAREXEL International, iGATE Corporation, iMEDGlobal Corporation, and inVentiv Health.

This report segments the global pharmacovigilance market as follows:

Global Pharmacovigilance Market: Clinical Trial Phase Analysis

  • Pre-Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

Global Pharmacovigilance Market: Service Provider Analysis

  • In-House
  • Contract Outsourcing

Global Pharmacovigilance Market: Method Analysis

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Global Pharmacovigilance Market: End-User Analysis

  • Hospitals
  • Research Organizations
  • Industries

Global Pharmacovigilance Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global pharmacovigilance market, 2016-2025 (USD Billion)
    • 2.2. Global pharmacovigilance market: Snapshot
  •  
  • Chapter 3. Pharmacovigilance Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global pharmacovigilance market drivers: impact analysis
      • 3.2.2. Increasing consumption of drugs fuels the continuous drug event monitoring demand
      • 3.2.3. The rising adoption of outsourcing services
    • 3.3. Market Restraints
      • 3.3.1. Global pharmacovigilance market restraints: impact analysis
      • 3.3.2. High risk associated with data security in pharmacovigilance outsourcing
    • 3.4. Opportunities
      • 3.4.1. Huge scope for the rapid growth of pharmacovigilance market in emerging economies
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by clinical trial phase
      • 3.6.2. Market attractiveness analysis, by service provider
      • 3.6.3. Market attractiveness analysis, by method
      • 3.6.4. Market attractiveness analysis, by end-user
      • 3.6.5. Market attractiveness analysis, by region
  •  
  • Chapter 4. Global Pharmacovigilance Market - Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global pharmacovigilance market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4. Research and development and regional expansion
    • 4.3. Price trend analysis
  •  
  • Chapter 5. Global Pharmacovigilance Market - Clinical Trial Phase Analysis
    • 5.1. Global pharmacovigilance market: clinical trial phase overview
      • 5.1.1. Global pharmacovigilance market revenue share, by clinical trial phase, 2018 and 2025
    • 5.2. Pre-Clinical
      • 5.2.1. Global pharmacovigilance market for pre-clinical, 2016-2025 (USD Billion)
    • 5.3. Phase 1
      • 5.3.1. Global pharmacovigilance market for phase 1, 2016-2025 (USD Billion)
    • 5.4. Phase 2
      • 5.4.1. Global pharmacovigilance market for phase 2, 2016-2025 (USD Billion)
    • 5.5. Phase 3
      • 5.5.1. Global pharmacovigilance market for phase 3, 2016-2025 (USD Billion)
    • 5.6. Phase 4
      • 5.6.1. Global pharmacovigilance market for phase 4, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Pharmacovigilance Market - Service Provider Analysis
    • 6.1. Global pharmacovigilance market: service provider overview
      • 6.1.1. Global pharmacovigilance market revenue share, by service provider, 2018 and 2025
    • 6.2. In-House
      • 6.2.1. Global pharmacovigilance market for in-house, 2016-2025 (USD Billion)
    • 6.3. Contract Outsourcing
      • 6.3.1. Global pharmacovigilance market for contract outsourcing, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Global Pharmacovigilance Market - Method Analysis
    • 7.1. Global pharmacovigilance market: method overview
      • 7.1.1. Global pharmacovigilance market revenue share, by method, 2018 and 2025
    • 7.2. Spontaneous Reporting
      • 7.2.1. Global pharmacovigilance market for spontaneous reporting, 2016-2025 (USD Billion)
    • 7.3. Intensified ADR Reporting
      • 7.3.1. Global pharmacovigilance market for intensified ADR reporting, 2016-2025 (USD Billion)
    • 7.4. Targeted Spontaneous Reporting
      • 7.4.1. Global pharmacovigilance market for targeted spontaneous reporting, 2016-2025 (USD Billion)
    • 7.5. Cohort Event Monitoring
      • 7.5.1. Global pharmacovigilance market for cohort event monitoring, 2016-2025 (USD Billion)
    • 7.6. EHR Mining
      • 7.6.1. Global pharmacovigilance market for EHR mining, 2016-2025 (USD Billion)
  •  
  • Chapter 8. Global Pharmacovigilance Market- End-User Analysis
    • 8.1. Global pharmacovigilance market: end-user overview
      • 8.1.1. Global pharmacovigilance market revenue share, by end-user, 2018 and 2025
    • 8.2. Hospitals
      • 8.2.1. Global pharmacovigilance market for hospitals, 2016-2025 (USD Billion)
    • 8.3. Research Organizations
      • 8.3.1. Global pharmacovigilance market for research organizations, 2016-2025 (USD Billion)
    • 8.4. Industries
      • 8.4.1. Global pharmacovigilance market for industries, 2016-2025 (USD Billion)
  •  
  • Chapter 9. Global Pharmacovigilance Market- Regional Analysis
    • 9.1. Global pharmacovigilance market: regional overview
      • 9.1.1. Global pharmacovigilance market revenue share, by region, 2018 and 2025
    • 9.2. North America
      • 9.2.1. North America pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
      • 9.2.2. North America pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
      • 9.2.3. North America pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
      • 9.2.4. North America pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.2.5. The U.S.
        • 9.2.5.1. The U.S. pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.2.5.2. The U.S. pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.2.5.3. The U.S. pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.2.5.4. The U.S. pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.2.6. Canada
        • 9.2.6.1. Canada pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.2.6.2. Canada pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.2.6.3. Canada pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.2.6.4. Canada pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
    • 9.3. Europe
      • 9.3.1. Europe pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
      • 9.3.2. Europe pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
      • 9.3.3. Europe pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
      • 9.3.4. Europe pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.3.5. UK
        • 9.3.5.1. UK pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.3.5.2. UK pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.3.5.3. UK pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.3.5.4. UK pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.3.6. Germany
        • 9.3.6.1. Germany pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.3.6.2. Germany pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.3.6.3. Germany pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.3.6.4. Germany pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.3.7. France
        • 9.3.7.1. France pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.3.7.2. France pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.3.7.3. France pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.3.7.4. France pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.3.8. Rest of Europe
        • 9.3.8.1. Rest of Europe pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.3.8.2. Rest of Europe pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.3.8.3. Rest of Europe pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.3.8.4. Rest of Europe pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
      • 9.4.2. Asia Pacific pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
      • 9.4.3. Asia Pacific pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
      • 9.4.4. Asia Pacific pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.4.5. China
        • 9.4.5.1. China pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.4.5.2. China pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.4.5.3. China pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.4.5.4. China pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.4.6. Japan
        • 9.4.6.1. Japan pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.4.6.2. Japan pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.4.6.3. Japan pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.4.6.4. Japan pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.4.7. India
        • 9.4.7.1. India pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.4.7.2. India pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.4.7.3. India pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.4.7.4. India pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.4.8. Rest of Asia Pacific
        • 9.4.8.1. Rest of Asia Pacific pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.4.8.2. Rest of Asia Pacific pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.4.8.3. Rest of Asia Pacific pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.4.8.4. Rest of Asia Pacific pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
    • 9.5. Latin America
      • 9.5.1. Latin America pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
      • 9.5.2. Latin America pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
      • 9.5.3. Latin America pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
      • 9.5.4. Latin America pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.5.5. Brazil
        • 9.5.5.1. Brazil pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.5.5.2. Brazil pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.5.5.3. Brazil pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.5.5.4. Brazil pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
      • 9.5.6. Rest of Latin America
        • 9.5.6.1. Rest of Latin America pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
        • 9.5.6.2. Rest of Latin America pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
        • 9.5.6.3. Rest of Latin America pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
        • 9.5.6.4. Rest of Latin America pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
    • 9.6. The Middle East and Africa
      • 9.6.1. The Middle East and Africa pharmacovigilance market revenue, by clinical trial phase, 2016-2025 (USD Billion)
      • 9.6.2. The Middle East and Africa pharmacovigilance market revenue, by service provider, 2016-2025 (USD Billion)
      • 9.6.3. The Middle East and Africa pharmacovigilance market revenue, by method, 2016-2025 (USD Billion)
      • 9.6.4. The Middle East and Africa pharmacovigilance market revenue, by end-user, 2016-2025 (USD Billion)
  •  
  • Chapter 10. Company Profile
    • 10.1. F. Hoffmann-La Roche
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Cognizant
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. Pharmaceutical Clinical Trial Phase Development
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Bristol-Myers Squibb
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. Covance
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. ICON
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. Accenture
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Therapy portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Pfizer
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Clinquest Group
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Therapy portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Novartis International
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments
    • 10.11. GlaxoSmithKline
      • 10.11.1. Overview
      • 10.11.2. Financials
      • 10.11.3. Product portfolio
      • 10.11.4. Business strategy
      • 10.11.5. Recent developments
    • 10.12. PAREXEL International
      • 10.12.1. Overview
      • 10.12.2. Financials
      • 10.12.3. Product portfolio
      • 10.12.4. Business strategy
      • 10.12.5. Recent developments
    • 10.13. iGATE Corporation
      • 10.13.1. Overview
      • 10.13.2. Financials
      • 10.13.3. Product portfolio
      • 10.13.4. Business strategy
      • 10.13.5. Recent developments
    • 10.14. iMEDGlobal Corporation
      • 10.14.1. Overview
      • 10.14.2. Financials
      • 10.14.3. Product portfolio
      • 10.14.4. Business strategy
      • 10.14.5. Recent developments
    • 10.15. inVentiv Health
      • 10.15.1. Overview
      • 10.15.2. Financials
      • 10.15.3. Product portfolio
      • 10.15.4. Business strategy
      • 10.15.5. Recent developments

Methodology

Free Analysis

The study of efficacy and safety in drugs and medical products is known as pharmacovigilance. Pharmacovigilance is the science that deals with collecting, detecting, assessing, and preventing adverse effects of medical products or drugs. It also analyzes the drugs’ side-effects and determines the ones that negatively affect the drug’s efficacy. It comprises of preclinical research, drug discovery and development, clinical research, post-marketing surveillance, etc. Every phase of the drug cycle is traced in pharmacovigilance, starting from its preclinical development stage to post-marketing surveillance.

The global pharmacovigilance market is driven by the rising awareness about the safety and efficacy of drugs among the worldwide population and the growing demand for substantially adopting safe medical practices. Emerging economies, such as India, China, and Brazil, have gathered momentum due to the increasing government support to open pharmacovigilance centers. This is further driving this global market’s growth. Additionally, the implementation of stringent post-market monitoring mechanism set by various government agencies for effective drug regulation system is also catalyzing the global pharmacovigilance market. The rising prevalence of adverse reactions caused due by drugs has inclined the biotechnological and pharmaceutical industries to adapt pharmacovigilance practices, which, in turn, is also expected to fuel this market in the future.

Global Pharmacovigilance Market

The global pharmacovigilance market is fragmented on the basis of clinical trial phase, service provider, method, and end-user. By clinical trial phase, the market includes pre-clinical, phase 1, phase 2, phase 3, and phase 4. By service provider, the pharmacovigilance market includes in-house and contract outsourcing. By method, the market involves intensified ADR reporting, targeted spontaneous reporting, spontaneous reporting, cohort event monitoring, and EHR mining. The end-user segment of the pharmacovigilance market is divided into hospitals, research organizations, and industries.

Europe is anticipated to hold a major share of the global pharmacovigilance market in the years ahead, due to the introduction of new laws by the European Union in 2012, which ensures good vigilance practices for medicine regulators and pharmaceutical companies. Rising prevalence of adverse drug reactions and the introduction of the new legislation have augmented the adoption of pharmacovigilance in many companies, which is fueling the European pharmacovigilance market growth. North America is estimated to hold the second largest share of the pharmacovigilance market globally in the future, due to the increasing number of research and development activities, substantial developments of new drugs, and flourishing biotechnology and pharmaceutical sectors in the U.S.

Some key players in the global pharmacovigilance market include as F. Hoffmann-La Roche, Cognizant, Pharmaceutical Clinical Trial Phase Development, Bristol-Myers Squibb, Covance, ICON, Accenture, Pfizer, Clinquest Group, Novartis International, GlaxoSmithKline, PAREXEL International, iGATE Corporation, iMEDGlobal Corporation, and inVentiv Health.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social